Novartis Announces its Avexis Unit Presents New Data at Epns Continuing to Show Significant Therapeutic Benefit of Zolgensma  in Prolonging Event-free Survival Now Up to 5 Years of Age in Patients With Spinal Muscular Atrophy Type 1